Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market October 17, 2025 - Baystreet.ca Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline trials through accelerated approval pathways, with FDA approvals incorporating increasingly diverse biomarkers from 3 in 2011 to 16 in 2022 as precision medicine advances target specific genetic mutations and molecular tumor characteristics[1]. AI-driven dose planning in radiation therapy enhances tumor targeting while reducing radiation exposure to healthy tissues, with machine learning algorithms forecasting tumor responses and optimizing treatment regimens for individualized care as artificial intelligence transforms precision cancer therapies through clinical decision support systems and individualized treatment planning[2]. This convergence of biomarker selection, targeted therapies addressing treatment resistance, immune activation platforms, and AI-guided precision delivery systems positions GT Biopharma, Inc. (NASDAQ: GTBP), Tango Therapeutics, Inc. (NASDAQ: TNGX), Kura Oncology, Inc. (NASDAQ: KURA), Corcept Therapeutics Incorporated (NASDAQ: CORT), and Accuray Incorporated (NASDAQ: ARAY). According to Precedence Research, the global precision oncology market reached $133 billion in 2025 and is predicted to surpass $312 billion by 2034, driven by increasing cancer prevalence and continuous advancement in genomic profiling techniques allowing more accurate and personalized therapies. Biomarker-driven treatment selection takes center stage as novel strategies for addressing platinum-resistant disease and difficult-to-manage cancer subtypes demonstrate improved outcomes, creating favorable conditions for companies developing targeted inhibitors addressing specific genetic vulnerabilities, immunotherapies activating natural killer cells, and robotic systems delivering precision radiation with artificial intelligence tracking and adapting for movement during treatment[4]. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing innovative immunotherapy treatments designed to combat some of the most challenging cancer types, with recent progress showing promise in its ongoing Phase 1 clinical trial of GTB-3650. The company has successfully enrolled both patients in the trial's third dosing group (Cohort 3), with neither patient experiencing concerning side effects or dose-limiting toxicities thus far. GT Biopharma expects to commence treatment for Cohort 4 patients before the end of 2025, with further data releases planned for early 2026. The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer cases to treat, involving patients whose disease either came back after initial therapy or never responded to conventional treatment options. GTB-3650 works by stimulating the patient's natural killer cells, a type of immune cell that naturally hunts down and destroys abnormal cells, to specifically target cancer cells. Patients receive the therapy through continuous infusions following a structured schedule: two weeks of treatment followed by two weeks of rest, repeating this cycle for up to four months based on how they respond. After thorough safety assessments, the company successfully advanced into Cohort 3 following formal reviews of the initial two patient cohorts that found no safety or tolerability issues. The early results are particularly encouraging based on biomarker data, objective biological measurements that indicate whether the drug is working as designed. Blood analysis from the first four patients revealed measurable increases in both natural killer cell activity and proliferation. The initial patient in Cohort 3 has shown encouraging signs of immune activation at levels comparable to those seen in patients from the earlier, lower-dose cohorts. This biological response suggests GTB-3650 is functioning precisely as intended: activating the immune system and directing it to attack cancer cells. The Phase 1 design calls for testing GTB-3650 in approximately 14 patients across seven cohorts, with two patients per cohort receiving progressively higher doses from 1.25μg/kg/day in Cohort 1 up to 100μg/kg/day in Cohort 7. The trial will continue escalating doses into higher ranges expected to translate immune activation into meaningful clinical benefits. "We are pleased with the enrollment momentum in our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which continues to advance on schedule," said Michael Breen, Executive Chairman and CEO of GT Biopharma. "Moving into the third dose cohort after a successful safety review and encouraging early evidence of immunological activity, mark important steps forward in the development of GTB-3650. We look forward to sharing more data later this year to reinforce the ability of our TriKE constructs to activate endogenous NK cells, and the potential for broader utility with other targets to treat solid tumors (GTB-5550) and autoimmune indications (GTB-7550)." Beyond blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma plans to file its regulatory application to begin human trials of GTB-5550 in the fourth quarter of 2025. GTB-5550 is being designed as a subcutaneous injection that patients might eventually self-administer at home. Both candidates utilize GT Biopharma's proprietary TriKE platform technology, which employs specialized antibody fragments originally found in camels and llamas. These molecules offer advantages over conventional antibodies due to their smaller size and greater stability. The company holds an exclusive worldwide license from the University of Minnesota for this technology. As of June 30, 2025, GT Biopharma reported approximately $5.3 million in cash and cash equivalents, with management projecting this capital would support operations through the first quarter of 2026. CONTINUED… Read this and more news for GT Biopharma, Inc. at: https://usanewsgroup.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ Tango Therapeutics, Inc. (NASDAQ: TNGX) will present first clinical data from its novel CoREST inhibitor TNG260 at the Society for Immunotherapy of Cancer Annual Meeting in November 2025. The company is evaluating TNG260 in combination with pembrolizumab in the dose expansion phase of its Phase 1/2 trial, currently enrolling patients with STK11-mutant/RAS wild type lung cancer, which represents approximately 10% of lung adenocarcinoma cases. "TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial," according to the company's announcement. "The trial is currently enrolling patients with STK11-mutant/RAS wild type lung cancer, approximately ~10% of lung adenocarcinoma." Tango Therapeutics will present three posters at SITC 2025, including preclinical data demonstrating that TNG260 sensitizes STK11-mutant tumors to anti-PD-1 therapy. The clinical-stage biotechnology company continues advancing its precision medicine approach using the genetic principle of synthetic lethality to discover and develop therapies targeting critical targets in cancer. Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd. have dosed the first patient in a new cohort of the KOMET-007 clinical trial evaluating ziftomenib combined with intensive chemotherapy and quizartinib for newly diagnosed acute myeloid leukemia patients. FLT3 mutations occur in approximately 30% of newly diagnosed adult AML patients and up to 50% of adult patients with NPM1-mutated AML, making FLT3 one of the most common genetic alterations in the disease. "Preclinical data demonstrate that ziftomenib synergizes with FLT3 inhibitors such as quizartinib, potentially enhancing activity without increasing toxicity," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "The KOMET-007 trial, alongside our recently launched KOMET-017 registrational trial combining ziftomenib with intensive and non-intensive chemotherapy, reflects our commitment to integrating menin inhibition across AML treatment regimens to improve patient outcomes." The trial will evaluate safety, tolerability and activity of the combination in adult patients with newly diagnosed FLT3-ITD/NPM1 co-mutated AML, with primary and secondary endpoints including complete remission and composite complete remission. Ziftomenib is the only menin inhibitor to have received Breakthrough Therapy Designation from the FDA for the treatment of adult patients with relapsed or refractory NPM1-mutated AML. Corcept Therapeutics Incorporated (NASDAQ: CORT) has submitted a Marketing Authorization Application to the European Medicines Agency for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The submission is based on positive data from the pivotal Phase 3 ROSELLA and Phase 2 trials, where patients receiving relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to nab-paclitaxel monotherapy, with no need for biomarker selection. "Our MAA submission brings us a step closer to our goal of delivering relacorilant to patients with platinum-resistant ovarian cancer," said Joseph Belanoff, M.D., Corcept's CEO. "Better treatment options are urgently needed. Relacorilant has the potential to redefine how platinum-resistant ovarian cancer is treated." The U.S. Food and Drug Administration is reviewing Corcept's application to market relacorilant in the United States with a PDUFA target action date of July 11, 2026. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe, facing a median overall survival of approximately 12 months with single-agent chemotherapy. Accuray Incorporated (NASDAQ: ARAY) announced that 5D Clinics has treated the first patients in Melbourne, Australia using the CyberKnife S7™ System in partnership with Icon Group. The number of new cancer cases diagnosed in Australia is projected to grow from 212,332 in 2022 to 318,285 in 2045, a nearly 50 percent increase that reinforces the need for innovative treatment options. "We couldn't be prouder to announce the first CyberKnife System patient treatments resulting from our partnership with the 5D Clinics and Icon Group joint venture," said Suzanne Winter, President and CEO of Accuray. "The CyberKnife System fills an unmet need in Australia to improve community access to this powerful technology that offers both personalized and precise cancer care treatments." The joint venture will open and operate CyberKnife System centers across Australia with an initial focus on the East Coast, making it easier for cancer patients to obtain state-of-the-art precision robotic stereotactic body radiation therapy and stereotactic radio surgery treatments closer to home. The CyberKnife S7™ System combines speed, precision, and artificial intelligence to track and automatically adapt for movement during treatment, typically completing procedures in just 1 to 5 outpatient sessions versus conventional fractionation which often requires 30-40 sessions. Article Sources: https://usanewsgroup.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Baystreet.ca on behalf of Market IQ Media Group Inc. ("MIQ"). Baystreet.ca is a wholly-owned entity of Baystreet.ca Media Corp. ("BAY"). BAY has not been paid a fee for the distribution of this article, but the owner of BAY also co-owns MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES 1. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3306?af=R 2. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-025-02369-9 3. https://www.precedenceresearch.com/precision-oncology-market https://www.onclive.com/view/emerging-adcs-biomarker-driven-treatments-and-diagnostic-advancements-take-center-stage-at-the-sgo-annual-meeting
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market October 17, 2025 - Baystreet.ca Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline trials through accelerated approval pathways, with FDA approvals incorporating increasingly diverse biomarkers from 3 in 2011 to 16 in 2022 as precision medicine advances target specific genetic mutations and molecular tumor characteristics[1]. AI-driven dose planning in radiation therapy enhances tumor targeting while reducing radiation exposure to healthy tissues, with machine learning algorithms forecasting tumor responses and optimizing treatment regimens for individualized care as artificial intelligence transforms precision cancer therapies through clinical decision support systems and individualized treatment planning[2]. This convergence of biomarker selection, targeted therapies addressing treatment resistance, immune activation platforms, and AI-guided precision delivery systems positions GT Biopharma, Inc. (NASDAQ: GTBP), Tango Therapeutics, Inc. (NASDAQ: TNGX), Kura Oncology, Inc. (NASDAQ: KURA), Corcept Therapeutics Incorporated (NASDAQ: CORT), and Accuray Incorporated (NASDAQ: ARAY). According to Precedence Research, the global precision oncology market reached $133 billion in 2025 and is predicted to surpass $312 billion by 2034, driven by increasing cancer prevalence and continuous advancement in genomic profiling techniques allowing more accurate and personalized therapies. Biomarker-driven treatment selection takes center stage as novel strategies for addressing platinum-resistant disease and difficult-to-manage cancer subtypes demonstrate improved outcomes, creating favorable conditions for companies developing targeted inhibitors addressing specific genetic vulnerabilities, immunotherapies activating natural killer cells, and robotic systems delivering precision radiation with artificial intelligence tracking and adapting for movement during treatment[4]. GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing innovative immunotherapy treatments designed to combat some of the most challenging cancer types, with recent progress showing promise in its ongoing Phase 1 clinical trial of GTB-3650. The company has successfully enrolled both patients in the trial's third dosing group (Cohort 3), with neither patient experiencing concerning side effects or dose-limiting toxicities thus far. GT Biopharma expects to commence treatment for Cohort 4 patients before the end of 2025, with further data releases planned for early 2026. The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer cases to treat, involving patients whose disease either came back after initial therapy or never responded to conventional treatment options. GTB-3650 works by stimulating the patient's natural killer cells, a type of immune cell that naturally hunts down and destroys abnormal cells, to specifically target cancer cells. Patients receive the therapy through continuous infusions following a structured schedule: two weeks of treatment followed by two weeks of rest, repeating this cycle for up to four months based on how they respond. After thorough safety assessments, the company successfully advanced into Cohort 3 following formal reviews of the initial two patient cohorts that found no safety or tolerability issues. The early results are particularly encouraging based on biomarker data, objective biological measurements that indicate whether the drug is working as designed. Blood analysis from the first four patients revealed measurable increases in both natural killer cell activity and proliferation. The initial patient in Cohort 3 has shown encouraging signs of immune activation at levels comparable to those seen in patients from the earlier, lower-dose cohorts. This biological response suggests GTB-3650 is functioning precisely as intended: activating the immune system and directing it to attack cancer cells. The Phase 1 design calls for testing GTB-3650 in approximately 14 patients across seven cohorts, with two patients per cohort receiving progressively higher doses from 1.25μg/kg/day in Cohort 1 up to 100μg/kg/day in Cohort 7. The trial will continue escalating doses into higher ranges expected to translate immune activation into meaningful clinical benefits. "We are pleased with the enrollment momentum in our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which continues to advance on schedule," said Michael Breen, Executive Chairman and CEO of GT Biopharma. "Moving into the third dose cohort after a successful safety review and encouraging early evidence of immunological activity, mark important steps forward in the development of GTB-3650. We look forward to sharing more data later this year to reinforce the ability of our TriKE constructs to activate endogenous NK cells, and the potential for broader utility with other targets to treat solid tumors (GTB-5550) and autoimmune indications (GTB-7550)." Beyond blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma plans to file its regulatory application to begin human trials of GTB-5550 in the fourth quarter of 2025. GTB-5550 is being designed as a subcutaneous injection that patients might eventually self-administer at home. Both candidates utilize GT Biopharma's proprietary TriKE platform technology, which employs specialized antibody fragments originally found in camels and llamas. These molecules offer advantages over conventional antibodies due to their smaller size and greater stability. The company holds an exclusive worldwide license from the University of Minnesota for this technology. As of June 30, 2025, GT Biopharma reported approximately $5.3 million in cash and cash equivalents, with management projecting this capital would support operations through the first quarter of 2026. CONTINUED… Read this and more news for GT Biopharma, Inc. at: https://usanewsgroup.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ Tango Therapeutics, Inc. (NASDAQ: TNGX) will present first clinical data from its novel CoREST inhibitor TNG260 at the Society for Immunotherapy of Cancer Annual Meeting in November 2025. The company is evaluating TNG260 in combination with pembrolizumab in the dose expansion phase of its Phase 1/2 trial, currently enrolling patients with STK11-mutant/RAS wild type lung cancer, which represents approximately 10% of lung adenocarcinoma cases. "TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial," according to the company's announcement. "The trial is currently enrolling patients with STK11-mutant/RAS wild type lung cancer, approximately ~10% of lung adenocarcinoma." Tango Therapeutics will present three posters at SITC 2025, including preclinical data demonstrating that TNG260 sensitizes STK11-mutant tumors to anti-PD-1 therapy. The clinical-stage biotechnology company continues advancing its precision medicine approach using the genetic principle of synthetic lethality to discover and develop therapies targeting critical targets in cancer. Kura Oncology, Inc. (NASDAQ: KURA) and Kyowa Kirin Co., Ltd. have dosed the first patient in a new cohort of the KOMET-007 clinical trial evaluating ziftomenib combined with intensive chemotherapy and quizartinib for newly diagnosed acute myeloid leukemia patients. FLT3 mutations occur in approximately 30% of newly diagnosed adult AML patients and up to 50% of adult patients with NPM1-mutated AML, making FLT3 one of the most common genetic alterations in the disease. "Preclinical data demonstrate that ziftomenib synergizes with FLT3 inhibitors such as quizartinib, potentially enhancing activity without increasing toxicity," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "The KOMET-007 trial, alongside our recently launched KOMET-017 registrational trial combining ziftomenib with intensive and non-intensive chemotherapy, reflects our commitment to integrating menin inhibition across AML treatment regimens to improve patient outcomes." The trial will evaluate safety, tolerability and activity of the combination in adult patients with newly diagnosed FLT3-ITD/NPM1 co-mutated AML, with primary and secondary endpoints including complete remission and composite complete remission. Ziftomenib is the only menin inhibitor to have received Breakthrough Therapy Designation from the FDA for the treatment of adult patients with relapsed or refractory NPM1-mutated AML. Corcept Therapeutics Incorporated (NASDAQ: CORT) has submitted a Marketing Authorization Application to the European Medicines Agency for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The submission is based on positive data from the pivotal Phase 3 ROSELLA and Phase 2 trials, where patients receiving relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to nab-paclitaxel monotherapy, with no need for biomarker selection. "Our MAA submission brings us a step closer to our goal of delivering relacorilant to patients with platinum-resistant ovarian cancer," said Joseph Belanoff, M.D., Corcept's CEO. "Better treatment options are urgently needed. Relacorilant has the potential to redefine how platinum-resistant ovarian cancer is treated." The U.S. Food and Drug Administration is reviewing Corcept's application to market relacorilant in the United States with a PDUFA target action date of July 11, 2026. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe, facing a median overall survival of approximately 12 months with single-agent chemotherapy. Accuray Incorporated (NASDAQ: ARAY) announced that 5D Clinics has treated the first patients in Melbourne, Australia using the CyberKnife S7™ System in partnership with Icon Group. The number of new cancer cases diagnosed in Australia is projected to grow from 212,332 in 2022 to 318,285 in 2045, a nearly 50 percent increase that reinforces the need for innovative treatment options. "We couldn't be prouder to announce the first CyberKnife System patient treatments resulting from our partnership with the 5D Clinics and Icon Group joint venture," said Suzanne Winter, President and CEO of Accuray. "The CyberKnife System fills an unmet need in Australia to improve community access to this powerful technology that offers both personalized and precise cancer care treatments." The joint venture will open and operate CyberKnife System centers across Australia with an initial focus on the East Coast, making it easier for cancer patients to obtain state-of-the-art precision robotic stereotactic body radiation therapy and stereotactic radio surgery treatments closer to home. The CyberKnife S7™ System combines speed, precision, and artificial intelligence to track and automatically adapt for movement during treatment, typically completing procedures in just 1 to 5 outpatient sessions versus conventional fractionation which often requires 30-40 sessions. Article Sources: https://usanewsgroup.com/2025/10/03/the-small-biotech-thats-cracking-the-code-big-pharma-paid-billions-for/ CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Baystreet.ca on behalf of Market IQ Media Group Inc. ("MIQ"). Baystreet.ca is a wholly-owned entity of Baystreet.ca Media Corp. ("BAY"). BAY has not been paid a fee for the distribution of this article, but the owner of BAY also co-owns MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of GT Biopharma, Inc. but reserve the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved on behalf of GT Biopharma, Inc. by CDMG; this is a paid advertisement. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. -- SOURCES 1. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3306?af=R 2. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-025-02369-9 3. https://www.precedenceresearch.com/precision-oncology-market https://www.onclive.com/view/emerging-adcs-biomarker-driven-treatments-and-diagnostic-advancements-take-center-stage-at-the-sgo-annual-meeting